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Abstract: Background: Experiments in the late nineties showed an inverse relationship in the
eye levels of melatonin and dopamine, thereby constituting an example of eye parameters that
are prone to circadian variations. The underlying mechanisms are not known but these relevant
molecules act via specific cell surface dopamine and melatonin receptors. This study investigated
whether these receptors formed heteromers whose function impact on eye physiology. We performed
biophysical assays to identify interactions in heterologous systems. Particular heteromer functionality
was detected using Gi coupling, MAPK activation, and label-free assays. The expression of the
heteroreceptor complexes was assessed using proximity ligation assays in cells producing the aqueous
humor and human eye samples. Dopamine D3 receptors (D3Rs) were identified in eye ciliary body
epithelial cells. We discovered heteromers formed by D3R and either MT1 (MT1R) or MT2 (MT2R)
melatonin receptors. Heteromerization led to the blockade of D3R-Gi coupling and regulation of
signaling to the MAPK pathway. Heteromer expression was negatively correlated with intraocular
hypertension. Conclusions: Heteromers likely mediate melatonin and dopamine actions in structures
regulating intraocular pressure. Significant expression of D3R–MT1R and D3R–MT1R was associated
with normotensive conditions, whereas expression diminished in a cell model of hypertension. A clear
trend of expression reduction was observed in samples from glaucoma cases. The trend was marked
but no statistical analysis was possible as the number of available eyes was 2.
Keywords: circadian rhythm; glaucoma; G-protein-coupled receptor GPCR heteromer; melatonin
MT1 and MT2 receptors; G protein coupling; mitogen-activated protein kinase pathway (MAPK);
label-free dynamic mass redistribution (DMR); retina; human 59HCE cells
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1. Introduction
The ciliary body, hidden behind the iris, is a complex, highly specialized tissue with a surface
containing a series of radially arranged structures known as ciliary processes [1], which are densely
vascularized and covered by highly active secretory cells to comply with the function of ciliary
processes, i.e., aqueous humor production [2].
The aqueous humor is a clear transparent fluid which bathes the anterior and posterior chambers
of the eye [3–5]. It participates in numerous functions such as providing nutrients to the cornea, lens,
and trabecular meshwork. More importantly, it also contributes to keeping the force that supports
intraocular tissue, thereby giving the eye a certain intraocular pressure (IOP) [6]. IOP is maintained
within normal values through a dynamic balance between its constant production by the ciliary
processes and its drainage. A lack of balance in the aqueous humor dynamics, usually leading to an
increment of IOP, is a significant risk factor in specific ocular pathologies such as glaucoma, the second
leading cause of blindness worldwide [7].
Several factors contribute to the homeostasis of IOP, among others, the episcleral vein pressure,
the ratio between production and drainage of aqueous humor, the influence of hormones, the innervation
by cranial nerves V and VII, and the circadian rhythm. Evidence showed that IOP follows variations
throughout the day, being maximal in the early morning and reaching its minimal levels during the
night [8]. These fluctuations are small, between 3–5 mm Hg, in healthy subjects. However, they are
significantly higher in the glaucomatous eye [9]. The primary modulator of eye circadian rhythms
seems to be melatonin.
Melatonin, an indoleamine that participates in the control of circadian rhythms, is a neurohormone
first identified in the pineal gland. However, a decade after its discovery by the dermatologist Aaron
Lerner and colleagues [10], it gained particular interest because of its multifunctional role. Apart from
being synthesized out of the pineal gland, melatonin is also considered an antioxidant and it contributes
to minimize the circadian disruption resulting from jet lag or in shift workers [11,12]. Melatonin is
synthesized by the retina [13] but, in subsequent studies, other sources were detected, namely, the iris,
the ciliary body [14], the crystalline lens [15,16], the Harderian gland [17] and the lacrimal gland [18].
It seems that melatonin can function directly as a free radical scavenger, but it mainly acts via specific
cell surface melatonin receptors.
In mammals, two melatonin receptors, MT1 (MT1R) and MT2 (MT2R) have been cloned and
characterized [19,20]. These receptors are present in numerous ocular structures; for instance, they are
expressed in the cornea, and among other functions, they accelerate corneal wound healing [21,22].
They mediate regulation of circadian rhythms and neuroendocrine processes in the retina and in
the non-pigmented ciliary body epithelium, which mediates IOP control (see References [23,24] and
references therein).
Melatonin receptors are members of the 7-transmembrane G protein-coupled receptor family
(GPCRs). Both MT1 and MT2 receptors belong to the class A of rhodopsin-like GPCRs (https:
//gpcrdb.org/) and contain seven hydrophobic transmembrane helices. Melatonin receptors have a
well-established canonical signaling pathway, where the stimulation of MT1R and MT2R results in
adenylate cyclase (AC) and protein kinase A inactivation by Gi-coupling [25–27]. However, it has been
reported that, depending on the tissue or the species studied, melatonin receptors could couple to other
G proteins to, for instance, activate phospholipase C-α (PLCα) [28] or inhibit guanylate cyclase (GC) [29].
Interestingly, studies show that the activation of melatonin receptors in the ciliary processes would lead
to an increase in cAMP levels [30]. Other possibilities include the influence derived from interactions
between these receptors and other receptors or other non-receptor proteins [31]. In this sense, direct
interactions between melatonin receptors and GPR50 have been reported. This orphan GPCR may
directly interact with the two melatonin receptors, although the interaction does not alter MT2R but
MT1R coupling to Gi [32]. The MT2R also interacts directly with 5-hydroxytryptamine 5HT2c receptors,
the heteromer leading to biased agonism for the melatonin receptor ligand, agomelatine [33]. Although
little is known about melatonin receptor heteromerization in the eye, a recent report has demonstrated
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the heteromerization of melatonin and α1-adrenergic receptors that alters canonical coupling as
heteromerization impedes coupling to the cognate G proteins, Gi and Gq, respectively [26,34].
Dopamine is present in eye structures, and the extracellular level of this neurotransmitter regulates
the synthesis of melatonin (in the eye) via dopamine receptors and cAMP as a second messenger [35–38].
The first evidence of an inverse correlation between dopamine and melatonin was found in the pigeon
eye. Microdialysis assays found that dopamine concentration decreased when melatonin levels
increased. In addition, melatonin injection suppressed the release of dopamine. Subsequent studies
in the same laboratory confirmed that melatonin/dopamine interactions were complex but relevant
for circadian rhythms in the eye [39,40]. However, the mechanisms underlying dopamine–melatonin
relationships in the eye have not yet been elucidated.
Dopamine receptors are grouped into two subfamilies: D1-like, which includes D1 and D5,
and D2-like, which includes D2, D3, and D4 [26]. Dopamine receptor expression has been addressed
directly in the retina. Dopamine D4 receptors were detected in the vertebrate retina [41] and D2
and D3 receptors were identified in the human retina by targeted mass spectrometry and positron
emission tomography [42]. Indirect evidence based on pharmacological assays and on responses in D3
receptor (D3R) KO mice showed that D3R activation leads to IOP reduction [43–45]. In preliminary
experiments, we have detected the D3 receptor in human ciliary body epithelial cells. The present work
aimed to address the potential interaction between dopamine D3 and melatonin receptors, along with
the functional consequences of these interactions. The expressions of D3R–MT1R and D3R–MT2R
heteroreceptor complexes were quantified in a ciliary body-based cell model of elevated IOP, and they
were assessed in samples from human normotensive and hypertensive eyes. The results proved
heteromerization and provided evidence of a negative correlation between ocular hypertension and
heteromer expression.
2. Materials and Methods
This work adhered to the guidelines detailed in Reference [46] and to the Helsinki declaration
regarding the ethics of working with human samples. The studies were designed to generate groups
of equal size, using randomization and blinded analysis. Immuno-based assays were conducted in
line with guidelines detailed in Alexander et al., 2018 [47].
2.1. Drugs
(RS)-trans-7-Hydroxy-2-[N-propyl-N-(3′-iodo-2′-propenyl)amino]tetralin (7-OH-PIPAT) maleate
(mixed D2R/D3R agonist), 3,5-Dichloro-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-6-
methoxybenzamide (raclopride: D3R antagonist), N-Acetyl-5-methoxytryptamine (melatonin),
N-qcetyl-2-benzyltryptamine (luzindole: non-selective MTR antagonist), N-[(1S)-1-[[4-[(2S)-2-[[(2,4-
dichlorophenyl)sulfonyl]amino]-3-hydroxy-1-oxopropyl]-1-piperazinyl]carbonyl]-3-methylbutyl]
benzo[b]thiophene-2-carboxamide (GSK1016790A: selective TRPV4 agonist), and cis-4-phenyl-2-
propionamidotetralin (4PPDOT, a selective MT2R antagonist) were purchased from Tocris Bioscience
(Bristol, UK). N-[2-(2-methoxy-6H-isoindolo[2,1-a]indol-11-yl)ethyl]butanamide (IIK7, a selective MT2
receptor agonist [48]) was purchased from Sigma-Aldrich (St. Louis, MO, USA).
2.2. Cell Culture and Transient Transfection
A human non-pigmented ciliary epithelial (59HCE) immortalized cell line was supplied by Dr.
Coca-Prados (Yale University). Cells were grown in high glucose Dulbecco’s modified Eagle’s medium
(Gibco/Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum (Sigma-Aldrich, St. Louis, MO,
USA) and 0.05 mg/mL penicillin/streptomycin (Gibco/Invitrogen) at 37 ◦C in a humidified atmosphere
of 5% CO2. After the culture reached the confluence, the cells were detached with 0.25% trypsin
and seeded into 6 well plates or glass coverslips. All the experiments were performed using cells
under 10–15 passages to assure assay reproducibility. Then, 59HCE cells were treated with a selective
Cells 2020, 9, 152 4 of 20
TRPV4 agonist, GSK1016790A (1–10,000 nM range), over 18 h, for the performance of the proximity
ligation assay.
HEK-293T cells grown in DMEM (Gibco/Invitrogen, Carlsbad, CA, USA) were processed as
previously described in References [49,50]. Briefly, HEK-293T cells growing in 6-well dishes were
transfected transiently with the corresponding cDNA using the PEI (PolyEthylenImine, Sigma-Aldrich,
St. Louis, MO, USA) method. The cells were incubated (for 4h) with the corresponding cDNA together
with PEI (5.47 mM in nitrogen residues) and 150 mM NaCl in a serum-starved medium. After 4 h,
the medium was replaced by a fresh complete culture medium.
2.3. Fusion Proteins and Expression Vectors
The human cDNAs for the D3, MT1, MT2, and GHS-R1a receptors cloned in pcDNA3.1 were
amplified without their stop codons using sense and antisense primers. The primers harbored either
unique BamHI and HindIII sites for D3; EcoRI and KpnI sites for GHS-R1a or Hind III; and BamH1 sites
for MT1 and MT2. The fragments were subcloned to be in frame with an enhanced yellow fluorescent
protein (pEYFP-N1; Clontech, Heidelberg, Germany) or an Rluc (pRluc-N1; PerkinElmer, Wellesley,
MA) on the C-terminal end of the receptor to produce D3-RLuc, MT1–YFP, MT2–YFP and GHS-R1a-YFP
fusion proteins.
2.4. Bioluminescence Resonance Energy Transfer (BRET) Assays
HEK-293T cells growing in 6-well plates were transiently co-transfected with a constant amount
of cDNA encoding for D3R fused to Renilla luciferase (D3-Rluc) and with increasing amounts of
cDNAs corresponding to MT1R, MT2R or ghrelin receptor GHS-R1a fused to the yellow fluorescent
protein (MT1-YFP, MT2-YFP, GHS-R1a-YFP). 48 h post-transfection cells were washed twice in quick
succession in HBSS (137 mM NaCl; 5 mM KCl; 0.34 mM Na2HPO4; 0.44 mM KH2PO4; 1.26 mM
CaCl2; 0.4 mM MgSO4; 0.5 mM MgCl2 and 10 mM HEPES, pH 7.4) supplemented with 0.1% glucose
(w/v), detached by gently pipetting and resuspended in the same buffer. To assess the number of
cells per plate, we determined protein concentration using a Bradford assay kit (Bio-Rad, Munich,
Germany) with bovine serum albumin dilutions as standards. To quantify YFP-fluorescence expression,
we distributed the cells (20 µg protein) in 96-well microplates (black plates with a transparent bottom;
Porvair, Leatherhead, UK). Fluorescence was read using a Mithras LB 940 (Berthold, Bad Wildbad,
Germany) equipped with a high-energy xenon flash lamp, using a 10-nm bandwidth excitation and
emission filters at 485 and 530 nm, respectively. YFP-fluorescence expression was determined as the
fluorescence of the sample minus the fluorescence of cells expressing protein-Rluc alone. For the
BRET measurements, the equivalent of 20 µg of cell suspension was distributed in 96-well microplates
(white plates; Porvair), and we added 5 µM coelenterazine H (PJK GMBH, Kleinblittersdorf, Germany).
Then, 1 min after coelenterazine H addition, the readings were collected using a Mithras LB 940
(Berthold, Bad Wildbad, Germany), which allowed the integration of the signals detected in the
short-wavelength filter at 485 nm (440–500 nm) and the long-wavelength filter at 530 nm (510–590 nm).
To quantify receptor-Rluc expression, we performed luminescence readings 10 min after addition of
5 µM coelenterazine H. The net BRET is defined as [(long-wavelength emission)/(short-wavelength
emission)]-Cf where Cf corresponds to [(long-wavelength emission)/(short-wavelength emission)] for
the Rluc construct expressed alone in the same experiment. The BRET curves were fitted assuming a
single phase by a non-linear regression equation using the GraphPad Prism software (San Diego, CA,
USA). BRET values are given as milli BRET units (mBU: 1000 × net BRET).
2.5. cAMP Level Determination
Two hours before initiating the experiment, 59HCE cells or HEK-293T cell-culture medium were
exchanged to serum-starved DMEM medium. Then, the cells were detached, re-suspended in growing
medium containing 50 µM zardaverine, and plated in 384-well microplates (2500 cells/well), pretreated
(15 min) with the corresponding antagonists—or vehicle—and stimulated with agonists (15 min)
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before adding 0.5 µM forskolin or vehicle. Readings were performed after 1 h incubation at 25 ◦C.
Homogeneous time-resolved fluorescence energy transfer (HTRF) measures were obtained using the
Lance Ultra cAMP kit (PerkinElmer, Waltham, MA, USA) (see Reference [51]). Fluorescence at 665 nm
was analyzed on a PHERAstar Flagship microplate reader equipped with an HTRF optical module
(BMG Lab technologies, Offenburg, Germany).
2.6. Extracellular Signal-Regulated Kinase Phosphorylation Assays
To determine extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation, 40,000 59HCE
or HEK-293T cells/well were plated in transparent Deltalab 96-well plates and kept in the incubator for
48 h. Then, 2 to 4 h before the experiment the medium was replaced by serum-free medium. The cells
were pre-treated at 25 ◦C for 10 min with antagonists or vehicle and stimulated for an additional 7 min
with selective agonists. The cells were then washed twice with cold PBS before the addition of lysis
buffer (a 20 min treatment). Afterward, 10 µL of each supernatant were placed in white ProxiPlate
384-well plates and ERK 1/2 phosphorylation was determined using an AlphaScreen®SureFire® kit
(Perkin Elmer), following the instructions of the supplier, and using an EnSpire® Multimode Plate
Reader (PerkinElmer, Waltham, MA, USA). The value of reference (100%) was the value achieved in
the absence of any treatment (basal). The effect of ligands was given in percentage with respect to the
basal value.
2.7. Label-Free Dynamic Mass Redistribution (DMR) Assay
Cell mass redistribution induced upon receptor activation was detected by illuminating the
underside of a biosensor with polychromatic light. We then measured the changes in the wavelength of
the reflected monochromatic light, which is a sensitive function of the index of refraction. The magnitude
of the wavelength shift (in picometers) is directly proportional to the amount of mass redistribution.
HEK-293T or 59HCE cells were seeded in 384-well sensor microplates to obtain 70–80% confluent
monolayers constituted by approximately 10,000 cells per well. Previous to the assay, the cells were
washed twice with assay buffer (HBSS with 20 mM HEPES, pH 7.15) and incubated for 2 h with
assay-buffer containing 0.1% DMSO (24 ◦C, 30 µL/well). Hereafter, the sensor plate was scanned, and a
baseline optical signature was recorded for 10 min before adding 10 µL of the selective antagonists for
30 min, followed by the addition of 10 µL of the selective agonists. All test compounds were dissolved
in assay buffer. Then, DMR responses elicited by the agonists were monitored for at least 5000 s in
an EnSpire® Multimode Plate Reader (PerkinElmer, Waltham, MA, USA). The results were analyzed
using EnSpire Workstation software v 4.10.
2.8. Human Eye Postmortem Samples
Donor human eyes were obtained from the Fundación Banco de Sangre y Tejidos de las Islas
Baleares (Balearic Islands Blood and Tissue Bank). This biobank is supervised by the regional
Balearic Islands Government, which is in charge of enforcing the principles in Helsinki declaration.
All donations are made after appropriate filling and signing of informed consent by patients or their
legal representatives. Two eyes of healthy normal subjects and two of glaucoma patients were used for
the assays. The eyes were enucleated and collected without the cornea in sterile tubes and maintained
in 4% paraformaldehyde in 0.1 M phosphate buffer (PB) (pH 7.2–7.4) at 4 ◦C until posterior processing.
Eyes were dissected under a stereomicroscope (Zeiss), with a 0.8 mm curved tip forceps and sterile
dissecting scissors, where we collected the iris and ciliary processes. Several washes in PBS were
performed, and then, the specimens were cryoprotected in a sucrose gradient (from 11% to 33%) and
embedded in tissue freezing medium (Tissue-Tek© OCT) until frozen with liquid N2. Vertical sections
of control and glaucomatous human samples (10 µm thick) were collected using a cryostat (Leica,
Nussloch, Germany) and were mounted from the same region. The samples were maintained at −20 ◦C
until use.
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2.9. Immunofluorescence Studies
HEK-293T cells were fixed in 4% paraformaldehyde for 15 min and then washed twice with PBS
containing 20 mM glycine before permeabilization with the same buffer containing 0.2% Triton X-100
(5 min incubation). The cells were treated for 1 h with PBS containing 1% bovine serum albumin
and labeled with a mouse anti-Rluc (1/100; MAB4400, Millipore) antibody and subsequently treated
with Cy3-conjugated anti-mouse (1/200; 715-166-150; Jackson ImmunoResearch (red)) IgG secondary
antibody (1 h each). Alternatively, cells were labeled with rabbit anti-D3R (#ab42114), anti-MT1R
(#ab203038), or anti-MT2R (#ab115336) antibodies, all from Abcam (Cambridge, UK) and subsequently
treated with Cy3-conjugated anti-rabbit (1/200; #711-166-152; Jackson ImmunoResearch (red)) IgG
secondary antibody (1 h each). The samples were washed several times and mounted with 30% Mowiol
(Calbiochem). Samples were observed under a Leica SP2 confocal microscope (Leica Microsystems).
2.10. In Situ and In Vitro Proximity Ligation Assay (PLA)
The proximity ligation assay (PLA) allows the detection of molecular interactions between two
endogenous proteins ex vivo. PLA requires both receptors to be sufficiently close (<16 nm) to allow
double-strand formation of the complementary DNA probes conjugated to the antibodies. Using the
PLA, the heteromerization of D3R with MT1 and MT2 receptors was detected in non-pigmented
epithelial ciliary body cells (59HCE) and, in situ, in the human ciliary body sections of healthy and
glaucomatous donors.
The presence/absence of receptor–receptor molecular interactions in the samples was detected
using the Duolink II In Situ PLA Detection Kit (developed by Olink Bioscience, Uppsala, Sweden;
and now distributed by Sigma-Aldrich as Duolink® using PLA® Technology). The PLA probes were
obtained after conjugation of the primary anti-D3R antibody (ab42114, Abcam, Cambridge, UK) to a
PLUS oligonucleotide (DUO92009, Sigma-Aldrich, St. Louis, MO, USA), and the anti-MT1R (ab203038,
Abcam, Cambridge, UK) and -MT2R (ab115336, Abcam, Cambridge, UK) antibodies to a MINUS
oligonucleotide (DUO92010, Sigma-Aldrich, St. Louis, MO, USA). The specificity of antibodies was
tested in non-transfected HEK-293T cells (see Appendix A Figure A3). Samples were fixed in 4%
paraformaldehyde for 15 min and then washed twice with PBS containing 20 mM glycine before
permeabilization with PBS-glycine containing 0.2% Triton X-100 (5 min incubation for the 59HCE
cells and 15 min for the ciliary body sections). After permeabilization, the samples were washed in
PBS at room temperature and incubated in a preheated humidity chamber for 1 h at 37 ◦C with the
blocking solution provided in the PLA kit. Then, the samples were incubated overnight with the PLA
probe-linked antibodies (1:100 dilution for all antibodies) at 4 ◦C. After washing, the samples were
incubated with the ligation solution for 1 h, and then washed and subsequently incubated with the
amplification solution for 100 min (both steps at 37 ◦C in a humid chamber). Nuclei were stained with
Hoechst (1/100; Sigma-Aldrich, St. Louis, MO, USA). Mounting was performed using 30% Mowiol
(Calbiochem). Negative controls were performed by omitting the anti-D3R-PLUS antibody. Samples
were observed using a Leica SP2 confocal microscope (Leica Microsystems, Mannheim, Germany)
equipped with an apochromatic 63× oil-immersion objective (N.A. 1.4), and with 405 nm and 561 nm
laser lines. For each field of view, we acquired a stack of two channels (one per staining) and 5 Z
planes with a step size of 1 µm. The ratio r (number of red spots/cell) was determined on the maximum
projection of each image stack using the Duolink Image tool software.
2.11. Data Analysis
Data, expressed as the mean ± SEM, were obtained from at least five independent experiments.
Data comparisons were analyzed by one-way ANOVA or two-way ANOVA, followed by Bonferroni’s
post-hoc test. The normality of populations and homogeneity of variances were tested before the
ANOVA. Statistical analysis was undertaken only when each group size was at least n = 5, n being
the number of independent variables (technical replicates were not treated as independent variables).
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Differences were considered significant when P ≤ 0.05. Statistical analyses were carried out with
GraphPad Prism software version 5 (San Diego, CA, USA). Outliers tests were not used, and all data
points (mean of replicates) were used for the analyses.
3. Results
3.1. Dopamine D3 Receptors Interact with Melatonin MT1 Receptors in the HEK-293T Cells
To determine whether the dopamine D3 receptor (D3R) could interact with the melatonin
MT1 receptor, we first performed immunocytochemical assays in a heterologous expression system.
HEK-293T cells were transfected with cDNAs coding for D3R-Rluc or MT1R-YFP. Expression of
D3R-Rluc was detected using an anti-Rluc primary antibody followed by a secondary Cy3-conjugated
antibody, and expression of MT1R-YFP was detected using the YFP’s fluorescence. Receptor expression
was found in different cell compartments, including the plasma membrane (Appendix A Figure A1A,
left and center panels). When the cells were co-expressing D3R-Rluc and MT1R-YFP, a significant
degree of co-localization was observed (yellow in Figure 1A).
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(A) Confocal microscopy images of HEK-293T cells co-expressing D3R-Rluc (2 μg) and MT1R-YFP (2 
μg). D3 receptor (red) was identified by immunocytochemistry using anti-Rluc antibodies. MT1 
receptor (green) was identified from the fluorescence of YFP-containing fusion proteins. Co-
localization is shown in the panel on the right (yellow). Cell nuclei were stained with Hoechst (blue 
channel). Scale bar: 20 μm. (B) Scheme of the bioluminescence resonance energy transfer (BRET) 
assay. (C,D) BRET saturation experiments performed using HEK-293T cells co-transfected with D3R-
Rluc cDNA (0.7 μg) and increasing amounts of MT1R-YFP cDNA (0–1.4 μg cDNA) (C) or GHSR-1a-
YFP cDNA (0–2.5 μg cDNA) as a negative control (D). BRET data are expressed as the mean ± S.D. 
of 8 different experiments performed in duplicates. mBU: milliBret units. HEK-293T cells transfected 
with cDNA encoding for D3R (1 μg) and MT1R (1 μg) were pre-treated or not with receptor 
antagonists (1 μM raclopride for D3R or 1 μM luzindole for MT1R) and then subsequently treated 
with agonists (100 nM 7-OH-PIPAT for D3R or 1 μM melatonin for MT1R), alone or in combination. 
(E) cAMP data were expressed as a % over 0.5 μM forskolin-induced levels. (F) ERK1/2 
phosphorylation was analyzed using an AlphaScreen®SureFire® kit (Perkin Elmer). ERK1/2 
. , .
l i i es of EK-293T cells co-expre sing D3R-Rluc (2 µg) and MT1R-YFP
(2 µg). D3 r ceptor (red) was identified by i cytoche istry i ti- l antib i s. 1
r c t r (gre n) was identified from the fluorescenc of YFP-containing fusion proteins. Co-localization
is shown in the panel o t e right (yellow). Cell nuclei were stained with Hoechst (blue channel). Scale
bar: 20 µm. (B) Scheme of the bioluminescence res nance energy transfer (BRET) assay. (C,D) BRET
saturation experiments performed using HEK-293T cells co-transfected with D3R-Rluc cDNA (0.7 µg)
and increasing amounts of MT1R-YFP cDNA (0–1.4 µg cDNA) (C) or GHSR-1a-YFP cDNA (0–2.5 µg
cDNA) as a negative control (D). BRET data are expressed as the mean ± S.D. of 8 different experiments
performed in duplicates. mBU: milliBret units. HEK-293T cells transfected with cDNA encoding for
D3R (1 µg) and MT1R (1 µg) were pre-treated or not with receptor antagonists (1 µM raclopride for D3R
or 1 µM luzindole for MT1R) and then subsequently treated with agonists (100 nM 7-OH-PIPAT for
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D3R or 1 µM melatonin for MT1R), alone or in combination. (E) cAMP data were expressed as
a % over 0.5 µM forskolin-induced levels. (F) ERK1/2 phosphorylation was analyzed using an
AlphaScreen®SureFire® kit (Perkin Elmer). ERK1/2 phosphorylation data are expressed as % with
respect to basal levels. In cAMP accumulation and MAPK activation assays, values are the mean± S.E.M.
of 6 different experiments performed in triplicates. One-way ANOVA followed by Bonferroni’s multiple
comparison post-hoc tests were used for statistical analysis. (*** p < 0.001; versus treatment with
forskolin in cAMP or basal in pERK assays). (### p < 0.001; versus treatment with 7-OH-PIPAT alone).
(&&& p < 0.001; versus treatment with melatonin alone). (G) label-free dynamic mass redistribution
(DMR) tracings are representing the picometer-shifts of reflected light wavelengths over time upon
ligand treatment.
As co-localization is not direct evidence of interaction, we used an energy-transfer biophysical
approach aimed at identifying direct physical interactions. Bioluminescence resonance energy transfer
(BRET) assays were performed in HEK-293T cells expressing a constant amount of D3R-Rluc and
increasing amounts of MT1R-YFP (Figure 1B). A saturation BRET curve was obtained (BRETmax
24.6 mBU, BRET50 14.9) (Figure 1C), indicating that D3R and MT1R physically interacted. As a negative
control, D3R was co-expressed with a non-interacting partner, the ghrelin receptor GHSR-1a. In this
case, the cells were co-transfected with a constant amount of D3R-Rluc and increasing amounts of
GHSR-1aYFP. A linear signal was obtained, indicating the lack of interaction between these receptors
(Figure 1D). These results indicated that D3 and MT1 may form heteroreceptor complexes in a
heterologous expression system.
3.2. Functional Characterization of D3-MT1 Heteroreceptor Complexes in HEK-293T Cells
Before estimating whether D3R and MT1R signaling properties were altered by D3R–MT1R
heteromerization, we performed assays in single-transfected cells. These preliminary assays consisted
of dose-response curves, to select the single agonist concentration for use in further assays performed
in cells expressing the two receptors. Cognate heterotrimeric G proteins are Gi/o for melatonin and
D3 receptors [26]. Thus, activation of these receptors leads to a decrease in cytosolic cAMP levels.
We have confirmed that this is the case in single transfected cells (Appendix A Figure A1B,C; see also
our recent report [52]), thereby reproducing data reported in References [34,53]. HEK-293T cells
expressing D3R or MT1 and incubated with the selective agonists, 7-OH-PIPAT for D3 and melatonin
for MT1, led to significant decreases in the forskolin-induced cytosolic cAMP levels. The blockade
was afforded by the respective antagonist, raclopride, or luzindole (Appendix A Figure A1B,C). Next,
we analyzed the mitogen-activated protein kinase (MAPK) signaling pathway, which may be mediated
by G-protein-dependent or independent mechanisms. Experiments performed in single-transfected
cells HEK-293T cells expressing D3R or MT1R led to a dose-response increase in phosphorylated
ERK1/2 levels, which was reversed by the respective antagonists (Appendix A Figure A2A,B). Finally,
we used a label-free approach based on the cell’s dynamic mass redistribution (DMR). Increasing
agonist concentrations were assayed in single-transfected HEK-293T cells expressing D3R or MT1R
treated with 7-OH-PIPAT or with melatonin, respectively. In both cases, we could observe significant
DMR outputs that were reverted by the respective antagonists (Appendix A Figure A2D,E).
Next, HEK-293T cells were transfected with both D3R and MT1R and then treated with 100 nM
7-OH-PIPAT and 1 µM melatonin, alone or in combination. Melatonin induced a decrease in the
forskolin-induced cAMP levels to a similar extent to that produced in cells only expressing MT1R.
In contrast, 7-OH-PIPAT did not produce any effect (Figure 1E). These results suggest that the
co-expression of MT1R blocks the 7-OH-PIPAT-induced D3R activation and Gi-mediated signaling.
The effect in simultaneous treatment with agonists was similar to that produced by melatonin alone.
When the cells were pre-treated with antagonists, we could observe that the melatonin effect was
not only abolished by the MT1R antagonist, luzindole, but also by the D3R antagonist, raclopride
(Figure 1E). This cross-antagonism, consisting of the antagonist of one receptor blocking the signal of
the partner receptor, is often found in GPCR heteroreceptor complexes.
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When the MAPK signaling pathway was analyzed in the HEK-293T cells co-expressing D3 and
MT1 receptors, a significant ERK1/2 phosphorylation was observed when the cells were treated with
7-OH-PIPAT or melatonin. These results showed that MT1R did not block 7-OH-PIPAT-induced D3R
signaling in the MAPK pathway (Figure 1F). Interestingly, the effect was much lower when the cells
were stimulated simultaneously with both agonists. Simultaneous co-activation resulting in reduced
signaling is known as negative cross-talk and has been reported for other GPCR heteromers. When cells
were pre-treated with antagonists, a bi-directional cross-antagonism was detected, which consisted
of the antagonists of either receptor blocking the activation of the partner receptor in the heteromer.
Indeed, the D3R antagonist raclopride inhibited not only the effect of 7-OH-PIPAT but also the effect of
melatonin, and the MT1R antagonist luzindole inhibited the effect of each agonist (Figure 1F).
DMR assays performed in the cells co-expressing D3R and MT1R led to results that were similar
to those observed in [cAMP] determination assays. While melatonin produced a significant effect
on DMR, 7-OH-PIPAT did not produce any effect (Figure 1G). When the cells were pre-treated with
antagonists, we observed a cross-antagonism phenomenon, as the melatonin effect was not only
inhibited by luzindole, but also by raclopride.
Together, the results showed that the consequences of D3-MT1 heteroreceptor complex formation
included a blockade of D3R-Gi coupling, a negative cross-talk in signaling towards the MAPK pathway,
and a cross-antagonism.
3.3. Dopamine D3 Receptors Interact with Melatonin MT2 Receptors in HEK-293T Cells
We considered the possibility of the D3R also interacting with the MT2R. Accordingly, we followed
the same strategy described earlier for MT1R. Immunocytochemical assays showed the presence of the
receptor in different cell compartments, including the cell membrane (Appendix A Figure A1A, right).
In double-transfected cells, a high degree of co-localization between D3R and MT2R was observed
(Figure 2A). Next, the BRET assay, schematized in Figure 2B, undoubtedly proved that D3R might
form heteroreceptor complexes with MT2R in a heterologous expression system. The saturation curve
was characterized by a BRETmax of 30.7 mBU and a BRET50 of 38.2.
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(A) Confocal microscopy images of HEK-293T cells co-expressing D3R-Rluc (2 µg) and MT2R-YFP
(2 µg). D3 receptor (red) was identified by immunocytochemistry using anti-Rluc antibodies. MT2
receptor (green) was identified from the fluorescence of YFP-containing fusion proteins. Co-localization
is shown in the panel on the right (yellow). Cell nuclei were stained with Hoechst (blue channel).
Scale bar: 20 µm. (B) Scheme of the BRET assay. (C) BRET saturation experiments performed using
HEK-293T cells co-transfected with D3R-Rluc cDNA (0.7 µg) and increasing amounts of MT2R-YFP
cDNA (0–2.3 µg cDNA). BRET data are expressed as the mean ± S.D. of 8 different experiments
performed in duplicates. mBU: milliBret units. Panels (D–F) Signaling in HEK-293T cells transfected
with cDNA encoding for D3R (1 µg) and MT2R (1 µg) were pre-treated with antagonists (1 µM
raclopride for D3R or 1 µM 4PPDOT for MT2R) or vehicle, and then subsequently treated with selective
agonists (100 nM 7-OH-PIPAT for D3R and 300 nM IIK7 for MT2R), individually or in combination.
(D) [cAMP] (expressed as % with respect to treatment with 0.5 µM forskolin) was detected by TR-FRET.
(E) ERK1/2 phosphorylation was analyzed using an AlphaScreen®SureFire® kit (Perkin Elmer). ERK1/2
phosphorylation data are expressed as % with respect to basal levels. In cAMP accumulation and
MAPK signaling assays, the values are the mean ± S.E.M. of 6 different experiments performed in
triplicates, and one-way ANOVA followed by Bonferroni’s multiple comparison post-hoc tests were
used for statistical analysis. (** p < 0.01, *** p < 0.001; versus treatment with forskolin in cAMP or basal
in pERK assays). (# p < 0.05, ### p < 0.001; versus treatment with 7-OH-PIPAT alone). (& p < 0.05, &&&
p < 0.001; versus treatment with IIK7 alone). (F) DMR tracings representing the picometer-shifts of
reflected light wavelengths over time upon ligand treatment.
3.4. Functional Characterization of the D3-MT2 Heteroreceptor Complexes in HEK-293T Cells
Dose-response assays in HEK-293T cells expressing MT2R were performed using a selective MT2R
agonist, IIK7. The results were consistent with Gi coupling, with MAPK activation, and with marked
DMR readings. Pretreatment with the MT2R antagonist 4P-PDOT blocked the MT2R agonist-induced
effect (Appendix A Figures A1D and A2C,F).
In forskolin-pretreated HEK-293T cells co-expressing D3R and MT2R, treatment with 7-OH-PIPAT
did not decrease cAMP levels, while IIK7 was able to produce a signal similar to that produced in
single-transfected cells. This result indicated that co-expression of MT2R blocks 7-OH-PIPAT-induced
Gi-mediated signaling (Figure 2D), in full resemblance to what was observed for the D3R–MT1R
heteromer. However, for the D3R-MT2R heteromer, no cross-antagonism was detected. When activation
of the MAPK pathway was analyzed in cotransfected HEK-293T cells, we observed the same phenomena
encountered for the D3R–MT1R heteromer. Both agonists were able to elicit a signal when used
separately but a negative cross-talk was detected in simultaneous co-activation. In this experiment,
the bi-directional cross-antagonism effect was observed, as both raclopride and 4P-PDOT were able
to block the signal elicited by either D3R or MT2R activation (Figure 2E). Finally, when the DMR
responses were analyzed, 7-OH-PIPAT did not produce any signal, while IIK7 produced a significant
effect. Again, as in the cAMP assays, no cross-antagonism was detected. The IIK7-induced signal
was only blocked by MT2R antagonist 4P-PDOT and not by the D3R antagonist raclopride. To sum
up, the results showed that the consequences of D3-MT2 heteroreceptor complex formation included
a blockade of D3R-Gi coupling and a negative cross-talk plus bi-directional cross-antagonism when
signaling towards the MAPK pathway was analyzed.
3.5. Detection and Functional Characterization of D3-MT1 and D3-MT2 Heteroreceptor Complexes in Human
Non-Pigmented Ciliary Body Epithelial Cells
To determine whether D3R–MT1R and D3R–MT2R heteromers occur in natural sources, we took
advantage of a technique that allows the detection of clusters of two receptors in fixed cells or tissue
sections, i.e., the in situ proximity ligation assay (PLA). The PLA was performed in the non-pigmented
human ciliary body epithelial 59HCE cell line, which expresses three receptors. Specific antibodies
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against D3, MT1, and MT2 receptors were used (see Appendix A Figure A3) and punctuated red marks
were visualized surrounding stained nuclei. This outcome demonstrated the existence of D3-MT1 and
D3-MT2 receptor complexes/clusters (Figure 3A, top and bottom left—0 nM).Cells 2020, 9, x FOR PEER REVIEW 11 of 20 
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Next, we studied the signaling properties of D3-MT1 and D3-MT2 heteroreceptor complexes in
the 59HCE cells using the approaches described in previous subsections. When cytosolic cAMP levels
were analyzed in the cells treated with 0.5 µM forskolin, the D3R agonist 7-OH-PIPAT, in agreement
with the heteromer’s print identified in the HEK-293T cells, did not produce any effect (Figure 4A,D).
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Interestingly, and as previously described by Alkozi et al., [34], none of the melatonin receptor
agonists, melatonin or IIK7, were able to decrease cAMP levels in these cells. Next, we analyzed ERK1/2
phosphorylation, which was significantly enhanced when 7-OH-PIPAT was added (Figure 4B,E).
When the cells were treated with 7-OH-PIPAT in combination with melatonin or with IIK7, a negative
cross-talk was observed, whereas a bi-directional cross antagonism occurred for both the D3R–MT1R
and D3R–MT2R heteromers. Finally, interpretation of the DMR data resulting from activation of the
receptors in the two heteromers was complex (Figure 4C,F). Perhaps the most relevant finding was the
bi-directional cross-antagonism detected for both D3R–MT1R and D3R–MT2R heteromers expressed in
the 59HCE cells. Apart from the evidence on heteromer formation, the results showed that neither D3,
MT1, or MT2 receptors were coupled functionally to Gi and that D3R–MT1R and D3R–MT2R signaling
was biased towards the MAPK pathway.
3.6. Differential Expression of D3-MT1 and D3-MT2 Heteroreceptor Complexes in the Glaucomatous Eye
We wondered whether intraocular hypertension correlated with the altered expression of dopamine
and melatonin heteroreceptor complexes. First of all, we took advantage of an in vitro model of
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hypertension, described in Reference [54], consisting of the activation of the transient receptor potential
vanilloid 4 (TRPV4) channel. Such activation in 59HCE cells using GSK1016790A mimics the ion
fluxes that drive the increase in hydrostatic pressure that occurs in the hypertensive/glaucomatous
eye. TRPV4 stimulation by application of the agonist, GSK1016790A, was followed by PLA to detect
the D3R-containing heteromers. Remarkably, increasing GSK1016790A concentrations translated
into a significant decrease in the PLA signal for D3-MT1 and D3-MT2 heteromers, and the effect
was dose-dependent. The reduction was up to 45% for D3R–MT1R heteromer expression, and up
to 95% in the case of D3R–MT2R heteromers (Figure 3A,B). Therefore, we could conclude that
mimicking glaucomatous conditions in a cell model reduces the expression of D3-MT1 and D3-MT2
heteroreceptor complexes.
Finally, exploratory experiments on heteromer expression were performed in the postmortem
samples obtained from glaucoma patients and age-matched controls. Given the limited availability
of these unique samples, which in part reflects ethical issues, we had access to two control (healthy)
and two glaucomatous eyes. Accordingly, statistical analysis could not be performed on the results
described below. PLA was performed in ciliary body sections of glaucoma patients and age-matched
controls. In the samples from normotensive eyes, marked expression of D3R–MT1R and D3R–MT2R
heteromers was found in the basal membrane of the non-pigmented epithelium. No heteromer
expression was found in the stroma of the ciliary processes (Figure 5A,D). A negligible PLA signal
was found in the negative controls performed by omitting one of the primary antibodies (Figure 5C).
When samples from glaucoma cases were analyzed, we observed a significant reduction in the number
dots for both heteromers (Figure 5B,E), with up to a 50% reduction in D3R–MT1R heteromer expression
and a reduction of up to 45% in the case of D3R–MT2R heteromers (Figure 5F). Together with the results
obtained in the 59HCE cells, these data point to a reduction of dopamine–melatonin heteroreceptor
complexes under conditions of elevated intraocular pressure.
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and glaucoma patients (B,E). Confocal microscopy images (superimposed sections) are shown. D3-MT1
(A,B) and D3-MT2 (D,E) receptor heteromers appear as red clusters and Hoechst-stained nuclei appear
in blue. (C) A negative control obtained by omitting one of the primary antibodies is shown. The ratio
(number of red spots/cell) for the indicated samples is shown in (F). Data are the mean ± S.E.M. of
counts in 6 different fields (each image covered an area of 238 µm2) from every sample from the controls
(n = 2) or glaucoma patients (n = 2). Scale bar: 40 µm.
4. Discussion
Dopamine, one of the primary neurotransmitters of the central nervous system, participates
in almost any higher-order function, from motor control to emotion control, and from cognition to
behavior. Dopamine is also a neurohormone acting in the periphery via the same receptors that are
expressed in the brain. The difference is that the relevant actions of dopamine are mainly exerted
by neuronal receptors, while in the periphery, these receptors are expressed in almost any kind
of cell type. A prospection study, made in our laboratory, showed the expression of the D3R in
different cells of the eye structure, including those that controlled IOP. These expression results fit
with pharmacological studies showing that different D3R agonists may lower IOP and that the effect
is lost in D3R-/- mice [43–45]. From earlier studies by the laboratory of S. George [55–57] it is known
that dopamine receptors may directly interact with themselves to form homodimers or with other
GPCRs. In a previous study, we also discovered D1-D3 heteroreceptor complexes with high relevance
in Parkinson’s disease-associated dyskinesia [53]. For these reasons, we explored whether the D3R
expressed in ocular structures could form functional heteromers with other GPCR of significant
relevance for eye physiology.
Melatonin is an example of a neurohormone produced by the pineal gland that may also be
produced (and released) elsewhere. Enzymes that participate in the synthesis of melatonin are
expressed in different cell types and the indoleamine participates in IOP regulation. Although the
retina was among the first identified structures able to synthesize melatonin [58,59], other eye cell
types express melatonin synthesizing enzymes (see 1. Introduction).
Our results decipher one of the mechanisms underlying the dopamine–melatonin interactions
described to occur in the eye. Based on prototypic heteromer prints that occur similarly in heterologous
expression systems and natural cell lines, and by further confirmation in natural sources by PLA,
we discovered novel physiologically relevant receptor–receptor interactions. The D3R, expressed in
ciliary body epithelial cells, may interact with either MT1R or MT2R. Canonical coupling of melatonin
receptors individually expressed in a heterologous system is to Gi (see References [25,52] and references
therein). Dopamine receptors are either coupled to Gs (D1 and D5) or Gi (D2, D3 and D4). Remarkably, in
the D3R–MT1R and the D3R–MT2R heteromer, the dopamine receptor did not couple to Gi but was still
functional, as dopamine receptor agonists could activate the MAPK pathway. Indeed, heteromerization
produced a biased functionality, i.e., a given agonist of the D3R, e.g., 7-OH-PIPAT may engage
Gi-mediated signaling but only in the right context [60]. Our results prove antagonistic interactions,
thus constituting a base to understand why the levels of dopamine and melatonin in the eye are
oppositely varying according to the 24-h circadian rhythm [39,40]. Not only the presence of melatonin
receptors and heteromer formation alters D3R-mediated signaling, but coactivation of receptors—in
heteromers—by moderate levels of the indoleamine and of dopamine would result in a decrease in
the overall signal transduction output. Accordingly, these heteromers mediate dopamine/melatonin
antagonistic actions in the eye.
Considering IOP regulation by melatonin, circadian rhythms, and opposite melatonin/dopamine
circadian levels in the eye; the results of heteromer expression in both a cell model of eye-related
hypertension, namely 59HCE cells treated with a TRPV4 agonist, and the human eye (from IOP
normotensive and hypertensive individuals) were relevant. They provided evidence of a correlation
between heteromer D3R–MT1R and D3R–MT2R complex disruption and elevated IOP. Despite the
few studies addressing GPCR heteromer expression in disease, often the results are quite relevant.
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On the one hand, they provide the basis for confirming whether the heteromer is expressed or not and,
accordingly, whether the heteromer may be a therapeutic target. On the other hand, the differential
functionality may lead to understanding of the consequences, at the signaling level, of the maintenance
or the disassembly of heteroreceptor complexes. This will provide reliable information on the
pathophysiology and factors affecting the course of the disease.
Based on our results, we think that future directions should include interventions assaying IOP
after infusions in the eye of a combination of melatonin and either D3R agonists or antagonists at
different times of the day in wild type animals and in a glaucoma animal model, such as the aged DBA/2J
mice [61,62]. From the results of such analysis, a potential therapy would arise for the assessment of
the hypertensive eye.
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Figure A1. Membrane receptor expression and cAMP responses in single-transfected HEK-293T 
cells. (A) Confocal microscopy images of HEK-293T cells transfected with cDNAs for D3R-Rluc (2 
μg), MT1R-YFP (2 μg), or MT2R-YFP (2 μg). D3 receptors (red) were identified by 
immunocytochemistry using anti-Rluc antibodies. MT1 and MT2 receptors (green) were identified 
from the fluorescence of YFP-containing fusion proteins. Cell nuclei were stained with Hoechst 
(blue channel). Scale bar: 20 μm. Panels (B–D) HEK-293T cells transfected with cDNAs encoding for 
D3R (1.5 μg) (B), MT1R (1.5 μg) (C) or MT2R (1.5 μg) (D) cells were pre-treated with vehicle or 
antagonists (1 μM raclopride for D3R, 1 μM luzindole for MT1R or 1 μM 4PPDOT for MT2R), and 
Figure A1. Membrane receptor expression and cAMP responses in single-transfected HEK-293T cells.
(A) Confocal microscopy images of HEK-293T cells transfected with cDNAs for D3R-Rluc (2 µg),
MT1R-YFP (2 µg), or MT2R-YFP (2 µg). D3 receptors (red) were identified by immunocytochemistry
using anti-Rluc antibodies. MT1 and MT2 receptors (green) were identified from the fluorescence of
YFP-containing fusion proteins. Cell nuclei were stained with Hoechst (blue channel). Scale bar:
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20 µm. Panels (B–D) HEK-293T cells transfected with cDNAs encoding for D3R (1.5 µg) (B), MT1R
(1.5 µg) (C) or MT2R (1.5 µg) (D) cells were pre-treated with vehicle or antagonists (1 µM raclopride
for D3R, 1 µM luzindole for MT1R or 1 µM 4PPDOT for MT2R), and then subsequently treated with
different concentrations of selective agonists (10–1000 nM 7-OH-PIPAT for D3R, 0.5–10 µM melatonin
for MT1R or 5–100 nM IIK7 for MT2R). cAMP accumulation was detected by TR-FRET in the presence
of 0.5 µM forskolin. cAMP production is expressed as % of levels obtained by 0.5 µM forskolin (0 nM
agonist). Values are the mean ± S.E.M. of 6 different experiments performed in triplicates, and one-way
ANOVA followed by Bonferroni’s multiple comparison post-hoc tests were used for statistical analysis.
(* p < 0.05, *** p < 0.001; versus treatment with forskolin). (### p < 0.001; versus treatment with 1 µM
melatonin or 100 nM IIK7 alone).
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Elmer). ERK1/2 phosphorylation data are expressed as % with respect to basal levels (0 nM agonist). 
Values are the mean ± S.E.M. of seven different experiments performed in triplicates, and one-way 
ANOVA followed by Bonferroni’s multiple comparison post-hoc tests were used for statistical 
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Figure A2. ERK phosphorylation and DMR responses in single-transfected HEK-293T cells. HEK-293T
cells transfected with cDNA encoding for D3R (1.5 µg) (A,D), MT1R (1.5 µg) (B,E), or MT2R (1.5 µg)
(C,F) were pre-treated with vehicle or antagonists (1 µM raclopride for D3R, 1 µM luzindole for MT1R,
or 1 µM 4PPDOT for MT2R), and then subsequently treated with different concentrations of agonists
(30–1000 nM 7-OH-PIPAT for D3R, 0.3–10µM melatonin for MT1R, or 3–1000 nM IIK7 for MT2R). ERK1/2
phosphorylation (A–C) was analyzed using an AlphaScreen®SureFire® kit (Perkin Elmer). ERK1/2
phosphorylation data are expressed as % with respect to basal levels (0 nM agonist). Values are the
mean ± S.E.M. of seven different experiments performed in triplicates, and one-way ANOVA followed
by Bonferroni’s multiple comparison post-hoc tests were used for statistical analysis. (* p < 0.05,
** p < 0.01, *** p < 0.001; versus basal). (## p < 0.001; versus treatment with 100 nM 7-OH-PIPAT alone).
(D–F) DMR tracings representing the picometer-shifts of reflected light wavelengths over time upon
agonist ligand treatment.
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Figure A3. The specificity of antibodies against D3, MT1, and MT2 receptors. Confocal microscopy 
images of the HEK-293T cells untransfected (bottom) or transfected with cDNAs coding for D3, MT1, 
or MT2 receptors (0.5 μg). The cells were treated with primary antibodies against either D3, MT1, or 
MT2 receptors (as indicated), and subsequently treated with a Cy3 secondary antibody (red). Images 
were taken near the bottom of the cell and, therefore, reflect the labeling in the membrane in contact 
with the slide. Cell nuclei were stained with Hoechst (blue channel). Scale bar: 20 μm. 
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